Actinomycin D
SIGMA/SBR00013 - Ready Made Solution, from Streptomyces sp., 2 mg/mL in DMSO
Synonym: Actinomycin D solution from Streptomyces sp.; Actinomycin IV; Dactinomycin
CAS Number: 50-76-0
Empirical Formula (Hill Notation): C62H86N12O16
Molecular Weight: 1255.42
Linear Formula: C62H86N12O16
Product Type: Chemical
| antibiotic activity spectrum | neoplastics |
| biological source | Streptomyces sp. |
| color | dark orange |
| concentration | 2 mg/mL in DMSO |
| description | Ready Made Solution |
| form | liquid |
| ready-to-use solution | |
| InChI | 1S/C62H86N12O16/c1-27(2)4 |
| InChI key | RJURFGZVJUQBHK-UHFFFAOYSA |
| mode of action | DNA synthesis | interferes |
| Quality Level | 200  |
| SMILES string | N21C(CCC2)C(=O)N(CC(=O)N( |
| storage condition | protect from light |
| storage temp. | −20°C |
| Application: | <ul> <li><strong>Regulation of Immune Checkpoints in Cancer:</strong> Actinomycin D is pivotal in studying the ADAR-mediated RNA editing processes that regulate PVR immune checkpoints in colorectal cancer, thus demonstrating its crucial role in cancer immunotherapy research and providing insights into novel therapeutic targets (Qian et al., 2024).  </li><li><strong>Chemotherapy and Immunotherapy Combination:</strong> The use of Actinomycin D in combined chemotherapy highlights its effectiveness in salvaging multi-chemotherapy agent and avelumab resistant choriocarcinoma, showcasing its potential in overcoming resistance to treatment in gynecological cancers (Lehmann et al., 2023). </li><li><strong>Advancements in Dental Medicine:</strong> Actinomycin D is used in regulating gene expression crucial for tissue regeneration and repair in dental health and it is also used to determine RNA stability assay (Pan et al., 2023). </li><li><strong>Cancer Progression Research:</strong> The study on hypoxia-induced lncRNA in hepatocellular carcinoma progression, where RNA-binding proteins play a critical role, aligns with Actinomycin D′s application in transcriptional inhibition and its influence on mRNA stability, essential for understanding cancer biology and developing targeted therapies (Tuo et al., 2023). </li></ul> |
| Biochem/physiol Actions: | Actinomycin D is an antineoplastic antibiotic that inhibits cell proliferation. It is a cytotoxic inducer of apoptosis against tumor cells. The compound inhibits the proliferation of cells in a nonspecific way by forming a stable complex with double-stranded DNA (via deoxyguanosine residues), thus inhibiting DNA-primed RNA synthesis. It also causes single strand breaks in DNA. Actinomycin D has been shown to be an inhibitor of the minus-strand transfer step in reverse transcription, and is therefore used in studies and suppression of HIV-replication. It has also been shown to suppress programmed cell death of PC12 cells induced by etoposide, an inhibitor of topoisomerase II. In cell culture, actinomycin D is used as a selection agent. Actinomycin D binding to yeast in ribosomal RNA has been studied. The sensitivity of various strains of E. coli to actinomycin D and the mechanism of binding has been studied. Actinomycin D is also used in molecular biology as a DNA intercalator which blocks the progression of RNA polymerases. |
| Disclaimer: | Actinomycin D solutions are very sensitive to light. |
| Packaging: | 1ML |
| Preparation Note: | The 2 mg/mL solution may be further diluted in an appropriate buffer prior to use. |
| Symbol |  GHS08 |
| Signal word | Danger |
| Hazard statements | H350 |
| Precautionary statements | P201 - P202 - P280 - P308 + P313 - P405 - P501 |
| WGK Germany | WGK 3 |
| Flash Point(F) | 188.6 °F - closed cup |
| Flash Point(C) | 87 °C - closed cup |
| Storage Temp. | −20°C |
| UNSPSC | 12352209 |